Topics

STAT Plus: Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective

09:36 EDT 29 Oct 2019 | STAT

An experimental vaccine from GlaxoSmithKline proved 50% effective at preventing latent tuberculosis infection from turning into active disease in a three-year study of adults in Africa.

Original Article: STAT Plus: Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective"

Quick Search

Relevant Topics

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...